Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials

Published:2014-10-20 Issue:1 Volume:12 Page:
ISSN:1741-7015
Container-title:BMC Medicine
language:en
Short-container-title:BMC Med

Author:

Giannetta Elisa,Feola Tiziana,Gianfrilli Daniele,Pofi Riccardo,Dall’Armi Valentina,Badagliacca Roberto,Barbagallo Federica,Lenzi Andrea,Isidori Andrea M

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://link.springer.com/article/10.1186/s12916-014-0185-3/fulltext.html

Reference57 articles.

1. Tsertsvadze A, Fink HA, Yazdi F, MacDonald R, Bella AJ, Ansari MT, Garritty C, Soares-Weiser K, Daniel R, Sampson M, Fox S, Moher D, Wilt TJ: Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009, 151: 650-661. 10.7326/0003-4819-151-9-200911030-00150.

2. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005, 353: 2148-2157. 10.1056/NEJMoa050010.

3. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D, Wang SH, Modry D, Archer SL: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation. 2003, 108: 2066-2069. 10.1161/01.CIR.0000099502.17776.C2.

4. Napoli C, Loscalzo J: Nitric oxide and other novel therapies for pulmonary hypertension. J Cardiovasc Pharmacol Ther. 2004, 9: 1-8. 10.1177/107424840400900i101.

5. Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ: Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med. 2012, 9: 271-281. 10.1111/j.1743-6109.2011.02504.x.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phosphodiesterase-5 inhibitors use and the risk of alzheimer's disease: a systematic review and meta-analysis;Neurological Sciences;2024-05-25

2. With great power comes great responsibility: the cardiovascular risk related to PDE5Is assumption;Minerva Urology and Nephrology;2024-05

3. Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment;Reviews in Cardiovascular Medicine;2024-03-06

4. Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism;The Aging Male;2023-12-26

5. Capillary leak and endothelial permeability in critically ill patients: a current overview;Intensive Care Medicine Experimental;2023-12-20